Latest news

• Boehringer's Spiriva combo approved in first EU markets

  s recently launched Striverdi product. .

• Boehringer bags FDA approval for Spiriva-based combo

  Stiolto contains the active ingredient in Spiriva - long-acting muscarinic antagonist (LAMA) tiotropium - with long-acting beta agonist (LABA) olodaterol that is sold as a monotherapy under the Striverdi brand name.

• FDA approves Boehringer COPD spray Striverdi Respimat

  Boehringer Ingelheim's once-daily chronic obstructive pulmonary disease (COPD) spray Striverdi Respimat (olodaterol) has won a US licence. ... As a long-acting beta-adrenergic agonist (LABA) Striverdi Respimat will, in common with other drugs in that

• Boehringer submits COPD combo in EU

  The drug combines Boehringer's huge selling Spiriva (tiotropium) with another of its respiratory treatments Striverdi (olodaterol). ... Striverdi is yet to hit the same lofty heights as Spiriva, having only received approval earlier this year.

• Novartis, Boehringer stake claims to combination COPD market

  up that combines tiotropium with the company's long-acting beta agonist Striverdi (olodaterol).